Sequencing and Biorepository Services
See a list of our services below.
DemyHealth’s Integrated Business Model
- Multi-platform business model: B2B and B2C
- Large, global market opportunities.
- Partnerships with agencies, organizations and biopharma companies.
- Innovation and expertise driven by key collaborations.
- Increasing growth and multiple revenue streams
There are many identifiable problems leading to obvious disparity in the African molecular diagnostic and Genomic Medicine space.
Molecular labs are struggling with stocking the right test kits, lab reagents and consumables.
Beyond pricing most labs are unable to properly select the right reagents with improved features that helps to avoid test reruns and prolong turnaround times. Scientists are faced with daily dilemma.
Most labs don’t have back up equipment such as PCR or Automated extractors. Non availability of Genomic Medicine tools such as Sequencers, Computational Infrastructure, Biobanking equipment, Nucleic acid Quantitators and Analyzers
Labs are green and are struggling with expanding their services beyond covid-19 PCR testing.
Labs don’t have access to competent engineers to carry out preventive maintenance of vital equipment.
Aside the basic DNA/RNA extraction and simple PCR detection, most Labs have little or no expertise in advance diagnostics and Genomic Medicine. Genomic medicine knowledge / tools are seriously lacking.
Organizations and companies participating in drug discovery and vaccine development are increasingly requiring cohort data inclusive of diverse population to undertake novel research and analysis for better disease understanding.
IMPACTS OF THE GAP
These gaps are responsible for the under develop African molecular diagnostic industry with paucity of African genomic data leading to disproportionate representation of African data in global genomics data.
This presents major limitation in the current drive towards precision medicine and modern drug discovery.
The world population stands at about 7.9 billion while Africa’s population is about 1.3 billion, but less than 3% of genomic data represented in global research is from African populations.
DemyHealth aims to narrow this disparity gap via our state-of-the-art biorepository which will be inclusive of clinical, phenotypic and genetic data of Africans.
HERE IS HOW WE SOLVE THESE PROBLEMS
Provide the labs with the needed capabilities by:
Stock up your lab with the right quantity of carefully selected reagents and consumables.
Keep the right stock of reagents that improve your laboratory’s efficiency, speed and quality results.
Making advance Genomic Medicine tool, training and services available, accessible and affordable.
At DemyHealth, one of our major goals is to tackle this gap in precision medicine by building one of the world’s largest biorepositories from the world’s most genetically diverse populations which will provide more accurate data-driven insights tailored for better health and therapeutics.
To achieve this, we have to implement infrastructure that enables:
- Provision of advanced Next Generation sequencing services to support research and clinical programs.
- Research that provides companies with data to create products that are inclusive of African populations.
- Provision of inclusive genomics data through our new biorepository.